HCA Healthcare Reports First Quarter 2026 Results: Key Takeaways for Investors

Strong Revenue Growth but Modest Profit Uptick

HCA Healthcare, Inc. (NYSE: HCA) has released its financial and operating results for the first quarter ended March 31, 2026. The report highlights continued growth in revenues and earnings per share, despite a challenging operating environment. Here are the key metrics and insights that investors need to know:

• Revenues increased by 4.3% year-over-year, reaching \$19.109 billion.
• Net income attributable to HCA Healthcare rose by 0.6% to \$1.620 billion.
• Diluted earnings per share (EPS) and adjusted diluted EPS climbed 10.9% to \$7.15 per share.
• Adjusted EBITDA increased by 1.9% to \$3.802 billion.
• Cash flows from operating activities surged 22.0% to \$2.014 billion.
• Same facility admissions grew by 0.9%, and same facility equivalent admissions by 1.3%.

Operational and Market Dynamics

CEO Sam Hazen acknowledged a “dynamic environment” at the start of 2026, praising HCA’s workforce for adaptability amid changing conditions. Notably, the company did not experience the usual seasonal volume increase in Q1, primarily due to a 42% decline in respiratory-related admissions and a 32% drop in respiratory-related ER visits, versus Q1 2025. A winter storm in January also dampened volumes in some markets.

These volume headwinds were largely offset by recognition of certain Medicaid supplemental programs that were not included in the company’s initial 2026 guidance, providing a positive impact to results.

Surgical and ER Metrics

• Same facility emergency room visits increased 0.3%.
• Same facility inpatient surgeries declined 0.3%.
• Same facility outpatient surgeries declined 1.7%.
• Same facility revenue per equivalent admission increased 3.1%.

Balance Sheet and Shareholder Returns

• As of March 31, 2026, cash and cash equivalents stood at \$940 million.
• Total debt was \$48.023 billion.
• Total assets reached \$61.450 billion.
• Capital expenditures (excluding acquisitions) were \$1.119 billion for the quarter.
• HCA repurchased 3.157 million shares at a cost of \$1.571 billion during Q1, with \$9.179 billion remaining under its current repurchase authorization.
• Dividend announced: \$0.78 per share, payable June 30, 2026, to shareholders of record on June 16, 2026.
• Availability under credit facility: \$4.336 billion as of March 31, 2026.

2026 Guidance Reaffirmed

HCA reaffirmed its previously issued 2026 guidance. Key assumptions include:

• Expectations of continued volume growth and a mostly stable operating environment.
• Guidance does not include potential future gains/losses on facility sales, debt retirement, legal claims, or impairment charges.
• Guidance also excludes impact of future approvals affecting Medicaid supplemental payments.

Full-year 2026 projections:

• Revenue: \$76.5 billion to \$80.0 billion
• Net income attributable to HCA: \$6.495 billion to \$7.035 billion
• Adjusted EBITDA: \$15.55 billion to \$16.45 billion
• Diluted EPS: \$29.10 to \$31.50 (based on 223.5 million diluted shares)

Operational Footprint

• As of March 31, 2026, HCA operated 189 hospitals and approximately 2,600 ambulatory sites of care (including surgery centers, freestanding ERs, urgent care centers, and physician clinics) across 19 states and the UK.

Risks and Forward-Looking Considerations

HCA’s forward-looking statements highlight several potential risk factors that could impact future results and share price. Notable risks include:

• Changes in economic conditions, inflation, tariffs, and trade policies.
• Potential reductions in patient volumes and changes in payer mix, especially with the expiration of enhanced premium tax credits (EPTCs) at the end of 2025, which could affect the number of insured patients.
• Labor cost pressures, supply chain disruptions, and workforce constraints.
• Possible reductions in Medicare and Medicaid payments, including state supplemental programs.
• Cybersecurity risks, natural disasters, and regulatory changes.

The company notes that many of these risks are outside its control, and future outcomes may differ materially from current guidance.

Shareholder-Relevant, Potentially Price-Sensitive Information

• EPS beat and strong operating cash flow: The 10.9% increase in diluted EPS and 22% jump in operating cash flow may be viewed positively by the market, particularly as it occurred despite volume headwinds.
• Significant buyback activity: Over \$1.5 billion in share repurchases in Q1 demonstrates ongoing commitment to shareholder returns, potentially supporting share price.
• Dividend continuity: The declaration of a \$0.78/share quarterly dividend signals confidence in cash generation.
• Guidance reaffirmation: The company’s maintenance of full-year guidance, despite industry and macroeconomic pressures, may be seen as a sign of underlying business strength.
• Medicaid supplemental program recognition: Recognition of programs not in original guidance provided a buffer against weak volumes—future changes in such programs could introduce volatility.
• Risks regarding payer mix and policy changes: The looming expiration of enhanced premium tax credits and potential Medicaid policy changes could materially impact future results.

Conclusion

HCA Healthcare delivered a solid start to 2026, overcoming volume headwinds with strong revenue growth, robust operating cash flow, and shareholder returns. The company’s reaffirmed guidance and continued buybacks signal management confidence, although investors should closely monitor evolving policy and volume trends, especially as the healthcare policy landscape shifts in 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a qualified financial advisor before making any investment decisions related to HCA Healthcare or any other security. The information provided herein is based on the company’s Q1 2026 report and is subject to change without notice.

View CapLand Ascendas REIT Historical chart here